anti rabies medicine use in preventing rabies after animal bite

Efficacy and safety of Equine rabies immunoglobulin (EquirabÂ®) in WHO Category III exposure subjects treated for post-exposure prophylaxis of rabies: a prospective, single arm, non-comparative study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023126

Enrollment

168

Registered

2020-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z203- Contact with and (suspected) exposure to rabies

Interventions

Intervention1: Equirab - Equine antirabies immunoglobulin: dose - 40IU/kg body weight to maximum of 3000 IU single dose administered irrespective of skin sensitivity test Control Intervention1: Not

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Category III exposure to Rabies

Exclusion criteria

Exclusion criteria: History of rabies vaccination Known allergy to immunoglobulins Suffering from a bleeding disorder Receiving treatment with immunosuppressive agents

Design outcomes

Primary

Measure	Time frame
Proportion of subjects achieving serum rabies virus neutralizing antibodies (RVNA) titre â?¥ 0.5 IU/mLTimepoint: On Day 14 post administration of IP	—

Secondary

Measure	Time frame
Number of subjects with mortality due to post-exposure prophylaxis failureTimepoint: End of study	—

Countries

India

Contacts

Public ContactDr Ganesh Divekar

Bharat Serums and Vaccines Ltd

Ganesh.divekar@bharatserums.com022-4503456

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026